On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- MHLW Approves Label Expansions for Olumiant, Gardasil, Lynparza and More
December 28, 2020
- MHLW Grants Orphan Status to 5 APIs
December 28, 2020
- Japan’s Drug Production Swells 37.3% to 9.5 Trillion Yen in 2019: MHLW Survey
December 28, 2020
- MHLW Drafts Guidelines for Use of Patient Registry Data in Regulatory Filing
December 25, 2020
- Japan Prepping to Expand Veklury Label beyond Severe COVID-19: PMDA
December 25, 2020
- Coronavirus Panel Draws Up Plan for Vaccination System, Priority
December 25, 2020
- Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
December 24, 2020
- MHLW to Disclose Members’ Names, Minutes of Drug Pricing, Cost-Effectiveness Analysis Organizations to Enhance Transparency
December 24, 2020
- Govt’s Reform Panel to Draw Up Framework by Next Summer for Permanent Telemedicine Rollout, with Reimbursement Policies
December 24, 2020
- MHLW’s FY2021 Budget Record 33 Trillion-Plus Yen
December 23, 2020
- MHLW Orders Label Revision for Xylocaine; Advising Careful Administration in Ears and Digits
December 23, 2020
- MHLW’s Health Policy Bureau Allocated 129 Million Yen for Setting Up R&D Promotion Network
December 23, 2020
- 700 Million Yen Allocated for COVID-19 Control Measures in FY2021: MHLW’s Pharm Safety Bureau
December 23, 2020
- 0.8% Add-On to Adjustment Rate Set to Soften Impact on Drug Distribution: MHLW
December 22, 2020
- MHLW Official Says Biz Suspension on Kobayashi Kako Inevitable
December 22, 2020
- MHLW to Draw Up Guideline for Collecting Plasma from People Recovering from Emerging Infectious Diseases
December 22, 2020
- MHLW Urges Drug Makers to Provide Timely, Appropriate Information When Product Shortages Occur
December 22, 2020
- Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
- Japan Govt to Compile Formulary Guidelines by FY2022: Reform Timeline
December 21, 2020
- Japan Saves 431.5 Billion Yen in Drug Price Cuts, Curbs Social Security Costs: FY2021 Draft Budget
December 21, 2020
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…